Back to search

Article

Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis

2021-05-03

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose </bold>Patients with preexisting autoimmune disease (PAD) are often excluded from clinical trials assessing immune checkpoint inhibitors (ICIs). Therefore, the safety of ICI therapy in patients with PAD remains unclear. Herein, we evaluated the incidence of immune-related adverse events (irAEs) in patients with PAD when compared with non-PAD patients.<bold>Methods </bold>W...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4d629b43-a0e9-59b9-9d22-9c8083eb3532
DOI
10.21203/rs.3.rs-403836/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysisDOI 10.21203/rs.3.rs-403836/v1
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodiesSemantic proximity
Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity
Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity
The Incidence of Immune Mediated Inflammatory Diseases Following COVID-19: a Matched Cohort Study in UK Primary CareSemantic proximity
Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework.Semantic proximity
Clinical Characteristics and Human Leukocyte Antigens in patients with Immune Checkpoint Inhibitor-induced Type 1 Diabetes and Pituitary Dysfunction: A single center prospective studySemantic proximity
Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity
Select a neighboring publication to make it the new centre.